Association of HSP90B1 genetic polymorphisms with efficacy of glucocorticoids and improvement of HRQoL in systemic lupus erythematosus patients from Anhui Province [0.03%]
热休克蛋白90家族成员B1基因多态性与安徽省系统性红斑狼疮患者糖皮质激素疗效及生活质量改善的关系研究
Xiu-Xiu Sun,Su-Su Li,Man Zhang et al.
Xiu-Xiu Sun et al.
Objective: The aim of this study was to investigate the associations between HSP90B1 gene polymorphisms and the efficacy of glucocorticoids (GCs) and the improvement of health-related quality of life (HRQoL) in Anhui patients with systemic ...
Neuroanatomical autonomic substrates of brainstem-gut circuitry identified using transsynaptic tract-tracing with pseudorabies virus recombinants [0.03%]
利用伪狂犬病毒重组物跨突触追踪技术鉴定脑干-肠道环路的神经解剖自主调节底物
Zhi-Gang He,Quan Wang,Run-Shan Xie et al.
Zhi-Gang He et al.
To investigate autonomic substrates of brainstem-gut circuitry identified using trans-synaptic tracing with pseudorabies virus (PRV)-152, a strain that expresses enhanced green fluorescent protein, and PRV-614, a strain that expresses enhan...
Reg3β from cardiomyocytes regulated macrophage migration, proliferation and functional skewing in experimental autoimmune myocarditis [0.03%]
心肌细胞源性的Reg3β调控实验性自身免疫性心肌炎中巨噬细胞迁移、增殖和功能偏向
Shanshan Zhou,Han Jiang,Han Wang et al.
Shanshan Zhou et al.
Macrophages play critical roles in inflammatory initiation, development, resolution and cardiac regeneration of myocarditis. However, Reg3β, as a member of regenerating family of proteins, contributes to dedifferentiation of injury cardiom...
Posterior reversible encephalopathy syndrome (PRES) attributed to mycophenolate mofetil during the management of SLE: a case report and review [0.03%]
一例利妥昔单抗治疗系统性红斑狼疮致可逆性后部脑病综合征的病例报告及文献复习
Lei Zhang,Jian Xu
Lei Zhang
Posterior reversible encephalopathy syndrome (PRES) is a rare clinical entity associated with systemic lupus erythematosus which characterized by seizure, headache, and altered mental status. The pathophysiology involves subcortical vasogen...
An immunohistochemical analysis of folate receptor beta expression and distribution in giant cell arteritis - a pilot study [0.03%]
巨细胞动脉炎中叶酸受体β表达与分布的免疫组化分析——一项前瞻性研究
Shirley Albano-Aluquin,Jozef Malysz,Vincent R Aluquin et al.
Shirley Albano-Aluquin et al.
Background: Giant cell arteritis (GCA) is a chronic vasculitis of large and medium vessels in which no targetable biomarkers exist to allow selective treatment, predict disease activity and monitor therapeutic responses. ...
The effect and safety of diacerein in patients with type 2 diabetes mellitus : a systematic review and meta-analysis [0.03%]
戴塞因在2型糖尿病患者中疗效和安全性：系统综述和meta分析
Qi Zhang,Junteng Zhou,Yushu Wang et al.
Qi Zhang et al.
The Background: Diacerein has been proposed as a treatment option for management of type 2 diabetes due to its anti-inflammatory properties. Purpose: The ...
Nayyab Asif,Razia Iqbal,Chaudhry Fahad Nazir
Nayyab Asif
A joint function of tissues, organs and cells for the protection of body develops immune system. The human immune response against various infections during sleep, its mechanism, neuroimmune interactions, immunoregulatory effect of sleep al...
Optimizing peptide epitope-based autoantibody detection in cancer patients [0.03%]
基于肽表位的自身抗体在癌症患者中的优化检测方法
Maize Wang,Shirley H Lomeli,Wilbur A Franklin et al.
Maize Wang et al.
Autoantibody (autoAb) response is an important arm of endogenously arising anti-tumor immune responses, and has received new attention as a cancer biomarker with the recent success of immune check-point inhibitor therapy. Our laboratory has...
New insights in the use of immunoglobulins for the management of immune deficiency (PID) patients [0.03%]
免疫球蛋白在原发性免疫缺陷患者治疗中的新进展
Gergely Krivan,Stephen Jolles,Eduardo Lopes Granados et al.
Gergely Krivan et al.
Immunoglobulin replacement therapy (IRT) is standard treatment for patients with primary immunodeficiency (PID). Because most of the patients with PID will require long life-time immunoglobulin replacement therapy, the quality of the prescr...
Combination of celecoxib (Celebrex®) and CD19 CAR-redirected CTL immunotherapy for the treatment of B-cell non-Hodgkin's lymphomas [0.03%]
西乐葆(Celebrex)联合CD19 CAR-重定向CTL免疫疗法治疗B细胞非霍奇金淋巴瘤
Tam Nm Dinh,Alexandra S Onea,Ali R Jazirehi
Tam Nm Dinh
The nonsteroidal anti-inflammatory drug (NSAID) Celecoxib (Celebrex®) received Food and Drug Administration (FDA) approval in 1998 for treatment of osteoarthritis and rheumatoid arthritis, and in recent years, its use has been extended to ...